Department of Anesthesiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China.
Int J Biol Sci. 2022 Jun 13;18(10):3981-3992. doi: 10.7150/ijbs.71491. eCollection 2022.
Intestinal ischemia/reperfusion (I/R) is a common pathophysiological process in clinical severe patients, and the effect of intestinal I/R injury on the patient's systemic pathophysiological state is far greater than that of primary intestinal injury. In recent years, more and more evidence has shown that intestinal microbiota and its metabolites play an important role in the occurrence, development, diagnosis and treatment of intestinal I/R injury. Intestinal microbiota is regulated by host genes, immune response, diet, drugs and other factors. The metabolism and immune potential of intestinal microbiota determine its important significance in host health and diseases. Therefore, targeting the intestinal microbiota and its metabolites may be an effective therapy for the treatment of intestinal I/R injury and intestinal I/R-induced extraintestinal organ injury. This review focuses on the role of intestinal microbiota and its metabolites in intestinal I/R injury and intestinal I/R-induced extraintestinal organ injury, and summarizes the latest progress in regulating intestinal microbiota to treat intestinal I/R injury and intestinal I/R-induced extraintestinal organ injury.
肠缺血/再灌注(I/R)是临床重症患者常见的病理生理过程,肠 I/R 损伤对患者全身病理生理状态的影响远远大于原发性肠损伤。近年来,越来越多的证据表明,肠道微生物群及其代谢物在肠 I/R 损伤的发生、发展、诊断和治疗中发挥着重要作用。肠道微生物群受宿主基因、免疫反应、饮食、药物等因素的调节。肠道微生物群的代谢和免疫潜能决定了其在宿主健康和疾病中的重要意义。因此,针对肠道微生物群及其代谢物可能是治疗肠 I/R 损伤和肠 I/R 诱导的肠外器官损伤的有效治疗方法。本综述重点关注肠道微生物群及其代谢物在肠 I/R 损伤和肠 I/R 诱导的肠外器官损伤中的作用,并总结了调节肠道微生物群治疗肠 I/R 损伤和肠 I/R 诱导的肠外器官损伤的最新进展。